Health and Fitness

Drug Policy Alliance

U.S. Sentencing Commission to Hold Hearing on MDMA and Several Novel Psychoactive Substances on Tuesday, April 18

Drug Policy Alliance: Time to Reduce the Role of Criminalization in MDMA and NPS Policies Washington, DC–(ENEWSPF)–April 17, 2017. On Tuesday, April 18 the U.S. Sentencing Commission (USSC) is holding a public hearing that will mark the beginning of a two-year process to reconsider the sentencing guidelines for MDMA as well as[Read More…]

FDA Approves First Drug to Treat Tardive Dyskinesia

Silver Spring, Maryland–(ENEWSPF)–April 17, 2017. The U.S. Food and Drug Administration approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition. Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips and[Read More…]

NIH Researchers Trace Origin of Blood-Brain Barrier ‘Sentry Cells’

An adult zebrafish brain showing fluorescent granular perithelial cells (green) atop blood vessels (purple). Finding in zebrafish may contribute to understanding cognitive decline of aging. Bethesda, Maryland–(ENEWSPF)–April 11, 2017.  National Institutes of Health researchers studying zebrafish have determined that a population of cells that protect the brain against diseases and[Read More…]

Hispanic and White Adolescents More Likely Than Black and Asian Peers to Develop Hypertension with Obesity

Elk Grove Village, IL—(ENEWSPF)—April 10, 2017.  Race and ethnicity may tip the scale on how often adolescents with obesity also develop hypertension, according to a new study in the May 2017 Pediatrics. For the study, “Race and Obesity in Adolescent Hypertension” (published online Monday, April 10), researchers measured the blood[Read More…]

FDA Approves Two Hepatitis C Drugs for Pediatric Patients

Silver Spring, Maryland–(ENEWSPF)–April 7, 2017. The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults. These are the first[Read More…]

FDA Allows Marketing of First Direct-to-Consumer Tests that Provide Genetic Risk Information for Certain Conditions

Silver Spring, Maryland–(ENEWSPF)–April 6, 2017. The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual’s genetic predisposition to certain[Read More…]

New Center for American Progress Report on Number of Americans with Pre-Existing Conditions by Congressional District

The U.S. Capitol dome is seen at dawn in Washington, March 2017. AP/ J. Scott Applewhite Washington, D.C. —(ENEWSPF)–April 7, 2017.  A new report by the Center for American Progress breaks down the number of Americans with pre-existing conditions by Congressional district. The new CAP numbers come amidst ongoing—but repeatedly[Read More…]

Most read stories this week

Take a Survey

ARCHIVES